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Purpose: Based on demonstrated ERβ-selective transcriptional activity in a cellular model, it was 
hypothesized that in vivo, efficacious doses of the novel ERβ agonist OSU-ERβ-12 could be 
determined that have minimal activity in ERα-dependent tissues. These doses were hypothesized 
to have an anti-fibrotic effect in a Non-Alcoholic Steatohepatitis (NASH) liver disease model.  
Design: We used uterotrophic stimulation in an estrogen-naïve female mouse model to assess 
ERα activity. Briefly, groups of mice were administered doses of the ERβ selective agonist 
OSU-ERβ-12 and compared to a control ERβ-selective ligand, LY500307. The ERα effects of 
each ligand were characterized using bodyweight-normalized uterine tissue weights. Then doses 
of OSU-ERβ-12 were given to mice treated with 6 weeks of CCl4 to establish efficacy of OSU-
ERβ-12 as an antifibrotic compound. Liver sections were stained with picrosirius red and the 
staining was then quantified using computer analysis.  
Results: OSU-ERβ-12 demonstrated ERβ-selective activity at doses <30 mg/kg, with 10 mg/kg 
being the highest selective dose. This dose was also efficacious at reducing the amount of 
fibrotic tissue picrosirius red staining seen in a liver section that was challenged with CCl4. 
LY500307 showed increased toxicity and decreased efficacy as compared to OSU-ERβ-12.  
Conclusions: Consistent with cellular activity data, uterotrophic stimulation data and the CCl4 
challenge data suggest that 10 mg/kg doses of OSU-ERβ-12 are both ERβ-selective and 






 Liver disease is a cause of ever-increasing concern to the world, as it is a largely unmet 
crisis in terms of healthcare. Liver disease that causes fibrosis in the form of Non-Alcoholic 
Fatty Liver Disease (NAFLD) or Non-Alcoholic SteatoHepatitis (NASH) predisposes patients to 
liver cancer, especially Hepatocellular Carcinoma (HCC). It is thought that NAFLD and NASH 
will soon overtake viral hepatitis as the leading cause of liver cancer worldwide. Because there is 
currently no approved therapy for NAFLD or NASH, any breakthroughs in this area have the 
potential to save or improve millions of lives (Bataller, 2005).  
 Liver disease is characterized by accumulation of fibrotic tissue in the liver, including 
collagen and other extracellular matrix proteins (Bataller, 2005). Fibrosis has many negative 
outcomes, including cirrhosis, liver failure, and liver cancers. Fibrosis in the liver is mostly 
thought to be permanent, and there is currently no way to treat NASH or associated liver failure 
outside of liver transplant. There are several therapeutics that aim to help reverse liver fibrosis or 
prevent fibrosis from advancing, spurred by recent studies in which some reversibility of liver 
fibrosis was seen in mice. There are currently no approved therapies for human patients with 
NASH, and so this is an urgent need in healthcare.  
 One of the vital premises for a study into potential estrogen therapeutics for the treatment 
of NASH is the presence of sexual dimorphism in liver cancer and liver fibrosis. Males have 
significantly higher rates of liver cancer than females, both in mice and humans, which indicates 
that liver cancer is somewhat reliant on sex hormone levels in the body. It is thought that 
estrogens may play some role in helping prevent or treat liver cancer and its precedent, sexually 
dimorphic conditions (Wu, 2019). The estrogen receptor is expressed in many different tissues 
within the body, including the uterus, ovaries, prostate, brain, breast, and bones. The estrogen 
receptor has two predominant forms; estrogen receptor α (ERα) and estrogen receptor β (ERβ) 
that are expressed in different amounts throughout the body. ERα is expressed in high amount in 
the uterus, breast and ovaries, as well as prostate and brain, while ERβ is expressed in the colon, 
prostate, ovary, bone marrow and brain. ERβ seems to be a good clinical target because of its 
implication in inflammation, cancer, and cardiovascular disease (Mohler, 2010).  
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Exogenous therapeutic estrogens that target estrogen-receptor α are well documented in 
the study of cancer, but have potentially lethal side effects and cause castration in males. It is 
therefore not desirable to treat cancers with non-selective estrogens like the most predominant 
endogenous estrogen, estradiol. However, it is theorized that ERβ can be selectively targeted to 
treat liver disease without the toxic effects from ERα. It is hoped that the antifibrotic effects seen 
in response to estrogens can be achieved by selectively modulating ERβ without stimulating 
ERα, bypassing the toxic side effects caused by ERα (Mohler, 2010).  
A medication of this nature would be considered a selective estrogen receptor modulator 
(SERM), and there is currently a compound that was tested as a potential ERβ selective SERM 
developed by Eli Lilly labelled LY500307. LY500307 is the most clinically advanced ERβ 
agonist, and is the class standard that will be analyzed in this paper. This molecule was analyzed 
in Phase I and II clinical trials but was ultimately abandoned due to lack of efficacy in prostatic 
disease (Clinical Trial# NCT01097707). The second medication that will be analyzed is a novel 
carborane compound developed at The Ohio State University by W. Tjarks, and it is one of the 
many carborane based estrogens that Tjarks developed and tested for potential selectivity and 
efficacy in vitro. The prospective compound that will be analyzed in this paper is the OSU-ERβ-
12, formerly known as WT-IV-12.  
The estrogen receptor selectivity for OSU-ERβ-12 and LY500307 were established using 
ERE-LUC (estrogen response element luciferase reporter assay) driven transactivation assay. In 
this assay, ER-null HEK293 cells were transiently transfected with either human ERα or ERβ, 
and the ability of increasing concentrations of each compound to stimulate expression of a 
luciferase transgene were assessed (Kim and Coss, 2013). Figure 1A shows the activation of the 
estrogen receptors in response to drug concentrations of the novel selective estrogen-receptor 






The estradiol control shows no initial separation in the stimulation of ERβ and ERα as is 
expected. However, OSU-ERβ-12 shows a distinct difference in the onset of receptor activity. 
The blue line represents the activity shown by ERβ, and the onset of transcriptional activity 
occurs at much lower concentrations of compound than ERα (>668 fold). These data support an 
opportunity for the development of ERβ selective dosing of this compound such that ERβ but not 
ERα are activated thus avoiding toxic effects of ERα. There is a similar trend for the class 
standard, the LY500307 compound made by Eli Lilly (Figure 1B, >1153-fold). The EC50 and 
the selectivity of the two novel compounds is shown in the table (Figure 1C), showing that both 
compounds have a significant window of selectivity, greater than ~500 fold each for ERβ. 
However, potency (EC50) of OSU-ERβ-12 for ERβ was reduced compared to LY500307, 
suggesting larger doses of OSU-ERβ-12, as compared to LY500307, are required for efficacy.  
Based on previous work showing the potential for ERβ-modulation to impact fibrotic 
liver disease (Zhang, 2013) (Ponnusamy, 2017) (Zhang, 2018),we hypothesized ERβ-selective 
doses of the novel carborane SERM OSU-ERb-12 could demonstrate anti-fibrotic efficacy 
absent ERα-mediated side effects. The following report demonstrates the process of establishing 
ERβ-selective dose levels and then testing their tolerability and anti-fibrotic efficacy in the CCl4 
model of fibrosis.  
Figure 1. ERE-LUC driven transactivation assay in HEK293 cells transiently 
transfected with either human ERα or ERβ. (A)OSU-ERβ-12 (WT) demonstrates 
ERβ selectivity, but reduced potency compared to 17-βE2. (B) LY500307 
demonstrates ERβ selectivity with similar potency to 17-βE2. (C) Tabulation of 
EC50 values for WT-IV-12 and LY500307 reveal ERB selectivity of ~500- and 









65 total C57/Bl6 female mice who were 20 days of age on day 0 were ear tagged and 
weighed in preparation for dosing the next day. Mice were randomly separated into treatment 
groups of 5 mice per group. Groups consisted of 5 different doses of the novel selective estrogen 
receptor modulator (SERM) OSU-ERβ-12, 4 different doses of the current class standard SERM 
LY500307 produced by Eli Lilly, an estradiol group, and three respective vehicle control groups. 
Doses of the OSU-ERβ-12 compound were 3, 10, 30, 100 and 300 mg/kg in a vehicle of 5% 
DMSO, 5% Tween 80 in water. Doses of the LY500307 compound were 0.03, 0.1, 0.3, and 1.0 
mg/kg in 1% MC, 0.25% Tween 80 in water. The two SERM compounds were dosed orally 
through gavage, along with the two corresponding vehicle controls. The estradiol group was 
dosed subcutaneously in corn oil as a 50 μg/kg dose with a subcutaneous corn oil vehicle control. 
Each mouse was weighed and dosed daily for 4 days. On the fifth day the mice were 
sacrificed, and tissue was collected. The uterus was extracted without puncturing, weighed, and 
then punctured and blotted to get both a wet weight with fluids inside the uterus and a blotted 
weight with the fluids removed. Cross sections of the uterine left horn were saved in formalin 
and imaged using 200x magnification. 
 
 
Figure 2. Diagram showing the treatment schedule for the uterotrophic assay. 
Mice were received, weighed, randomized, and ear tagged on Day 0, weighed and 
dosed with treatment compounds on Day 1-4, and sacrificed on Day 5.  
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80 total C57/Bl6 male mice were randomly assigned to treatment groups with 10 mice 
per treatment group. All groups were treated with escalating doses of 50:50 carbon tetrachloride 
(CCl4) for six weeks through oral gavage (Kim, 2017). The stage of fibrosis was determined by 
the length of CCl4 administration as shown by a previous pilot study. (Helms) Based on this pilot 
work, at 4 weeks of CCl4 administration mice were expected to have the equivalent of human F2 
stage liver fibrosis as confirmed by histological analyses. Treatment with intervention 
compounds was started in the 4th week, with seven different treatment groups (Figure 2). One 
group was not treated to help characterize potential spontaneous fibrosis resolution. Treatment 
groups included an estradiol group of 82 μg/kg in 5% DMSO in corn oil, 10 and 100 mg/kg 
treatment groups of the novel SERM OSU-ERβ-12 in 5% DMSO, 5% Tween80 in water, and a 5 
mg/kg group of the class standard SERM LY500307. There were also three vehicle groups, one 
Figure 3. Diagram showing treatment plans for each mouse group. One group 
dosed with only CCl4 for six weeks, and all other mouse groups treated with CCl4 
for six weeks with intervention treatment starting on the fourth week. Seven 
intervention treatment groups; Sub-cutaneous (SC) estradiol and SC vehicle, PO 
OSU-ERβ-12 (WT) compound in doses of 10 mg/kg and 100 mg/kg as well as the 




for each of the treatments. The estradiol group and 5% DMSO and corn oil vehicle were both 
dosed subcutaneously, while all other treatment groups were dosed orally through gavage. 
Estradiol was included here as a positive control as there is established efficacy in preventing 
NAFLD and NASH in other CCl4 models (Liu, 2004) (Besse-Patin, 2017). CCl4 treatment 
continued for another 2 weeks and was then stopped. The group not treated with an intervention 
was then sacrificed to characterize spontaneous fibrosis resolution and baseline fibrosis. The 
primary objective was to quantitatively assess fibrosis through picrosirius red (PSR) staining of 
collagen deposits. Picrosirius red staining is a way to visualize collagen in liver fibrosis, and can 
be quantified through computer imagining (Standish, 2006). A secondary objective of this 
experiment was to determine if there were toxic ERα effects present in male mice by looking at 








The goal of these experiments was to establish the efficacy of the novel SERM OSU-
ERβ-12 and to establish a dose that was shown to be selective for estrogen receptor β. A 
selective dose first needed to be established to determine the doses that would be tested in the 
liver fibrosis efficacy model.  
The uterotrophic assay was chosen to help establish a selective dose of OSU-ERβ-12 
because uterine weight of estrogen naïve mice is a potent indicator of estrogen receptor α activity 
(Mohler, 2010). A small amount of ERα activity will cause measurable effects on an estrogen 
naïve uterus, such that a dose of a compound that does not cause an increase in uterine weight 
should be ERβ selective. We hypothesized that the highest dose group absent ERα stimulation is 
the highest ERβ selective dose. 
A CCl4 liver fibrosis model was used to demonstrate extensive fibrosis similar to the 
fibrosis seen in NASH, and to test the ability of multiple therapeutic estrogens to treat ongoing 
fibrosis in the context of an existing fibrotic burden. Fibrosis is an important indicator of disease 
because it is strongly related to patient outcomes and often dictates treatment (Hagström, 2017). 
In the CCL4 model, fibrotic pathology is distinct from those as seen in metabolic disorder caused 
by obesity, but as a well-established model it has notable benefits and drawbacks (Oligschlaeger, 
2020). 
 Urogenital tract atrophy and biomarkers for hepatic cholestasis were also measured in the 





ERβ Selective Dosing of OSU-ERβ-12 
The uterotrophic assay is intended to determine a dose that is free from toxic ERα effects 
in C57Bl/6 estrogen naïve female mice. This assay shows that at doses < 30 mg/kg there is no 
uterine stimulation in OSU-ERβ-12 (WT) as determined by blotted uterine weight relative to 
body weight (Figure 4A). There was no uterine stimulation for any of the LY doses 
administered. (Figure 4B) 
A histological analysis of the OSU-ERβ-12 (WT) compound at a low and high dose 
levels compared both to the OSU-ERβ-12 (WT) vehicle and estradiol shows lack of stratification 
of endometrial cells in the vehicle control and 3 mg/kg dose of OSU-ERβ-12 (WT). The vehicle 
and 3 mg/kg groups show normal juvenile uterine histomorphology: single layer of columnar 
endometrial epithelium, and a densely populated endometrial stroma. (Figure 5A and 5C) The 
high 100 mg/kg dose of OSU-ERβ-12 (WT) shows histomorphological features consistent with 
exposure to estrogens: hyperplastic, stratified endometrial epithelium, and hypertrophied, 




Establishing Efficacy of OSU-ERβ-12 in a CCl4 Liver Fibrosis Model 
After six weeks of oral CCl4 dosing, the first group of mice (only treated with CCl4 and 
no intervention) were sacrificed to help show a baseline of fibrosis at the end of the CCl4 
challenge. When compared to vehicle treated mice sacrificed 2 weeks later, these data also show 
how much fibrosis spontaneously resolves following cessation of CCl4 administration. (Figure 
6A) The three vehicle control groups were compared to the CCl4 group with the assumption that 
the vehicle control does not help reduce fibrosis, and so any resolution of fibrosis after the 
cessation of CCl4 administration was spontaneous and not treatment related. The CCl4 group 
shows a significant difference in the amount of fibrosis seen through PSR staining of histological 
liver section (Figure 6B) as compared to all three vehicle control groups. Vehicle control groups 
were also treated for six weeks with CCl4, but vehicle administration began on week four and 
continued for two weeks after cessation of CCl4 administration (Figure 2).  
After treatments was concluded on week eight, all mouse groups were sacrificed and PSR 
staining in treatment groups were compared to the vehicle controls. All treatment groups were 
compared to their respective vehicle controls. Subcutaneous estradiol did not reduce PSR 
staining when compared to its vehicle control (Figure 7A), with the histological representation 
of this in Figure 7B.  
There was a significant reduction of PSR staining in the LY500307 liver slides (Figure 
8A), with a p value of 0.0404 following a Tukey’s multiple comparisons test analysis. The 
histological staining visually shows this reduction as well (Figure 8B).  
The OSU-ERβ-12 compound (Abbreviated here as WT), shows a marked decrease in 
PSR staining. (Figure 9A) This trend is seen for both doses, showing that a lower dose of the 
OSU-ERβ-12 compound is still efficacious at reducing PSR staining in a CCl4 fibrosis model 
(Figure 9B).  
Alkaline Phosphatase (ALP) is a marker for hepatic cholestasis, because an increase in 
serum ALP shows decreased or stopped bile flow from the liver (Alvaro, 2006). Estrogens have 
been shown to induce hepatic cholestasis, which is a toxic effect caused by damage or blockage 
to the biliary ducts of the liver (Alvaro, 2006). Estradiol and 5 mg/kg LY500307 both show a 
significant increase in ALP, but OSU-ERβ-12 only shows a significant increase in ALP at the 
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high dose of 100 mg/kg. The low, efficacious, 10 mg/kg dose of OSU-ERβ-12 does not show a 
significant increase in serum ALP levels.  
Urogenital tract weight atrophy (standardized to body weight) is an indicator of ERα 
toxicity in hormone sensitive male secondary sex organs. This is thought to be due to ERα-
mediated suppression of androgen synthesis through the hypogonadal-pituitary-gonadal (HPG) 
axis (Lindzey, 1998). In this study, the UGT tract included the seminal vesicle, coagulating 
gland, prostate and urinary bladder. Samples were standardized to individual body weights and 
compared to their corresponding vehicle controls. There is a significant reduction in UGT weight 
for all groups from their respective vehicle for all groups except for the 10 mg/kg OSU-ERβ-12 
(WT) group. Tukey’s multiple comparisons test E2 and LY groups differed from their respective 
controls (p<0.0001) and OSU-ERβ-12 (WT) differed from the OSU-ERβ-12 (WT) vehicle 
(p=0.0054) (Figure 11A). The 10 mg/kg OSU-ERβ-12 (WT) group was then compared to both 
the LY and E2 groups directly, and there is significantly less UGT weight reduction in the OSU-
ERβ-12 (WT) 10 mg/kg group as compared to these groups.  
There was no significant reduction in testes weight for the LY500307 compound or OSU-
ERβ-12 (WT) compound at either dose, although both the LY dose and 100 mg/kg OSU-ERβ-12 
(WT) dose showed a downward weight trend. The estradiol showed significant testes weight 





 This report has shown that ERβ agonism is a viable therapeutic approach to address liver 
fibrosis like that seen in NASH. Both LY500307 and OSU-ERβ-12 showed efficacy at doses 
shown to be ERβ selective, but this effect was not seen in the estradiol treated mice, indicating 
that ERβ modulation alone is producing this antifibrotic effect, and not ERα or a non-selective 
therapeutic estrogen. Our data indicate that it is possible to selectively target ERβ to achieve 
estrogen related effects absent the side effects that come from unwanted ERα such as 
thromboembolic events or UGT atrophy in males.  
Though the high 100 mg/kg dose of OSU-ERβ-12 showed some efficacy in the CCl4 liver 
fibrosis model, it showed increased toxicity and was deemed to be an unselective dose because 
of the estrogenic activity seen in the uterotrophic assay. However, selective doses of OSU-ERβ-
12 are readily achieved in mice, with the highest selective dose being 10 mg/kg. This dose was 
also deemed to be efficacious in the CCl4 liver fibrosis model.  
 This compound has incredible potential in therapeutics to be one of the first treatments 
for NASH, both as a preventative and a treatment that can help reduce current fibrosis levels. 
This compound shows improved selectivity and toxicity as compared to the previous class 
standard, LY500307. The 10 mg/ kg selective dose of OSU-ERβ-12 shows significantly less 
UGT deterioration and cholestasis in male mice as compared to LY500307. Though LY500307 
was shown to be efficacious at a dose of 5 mg/kg, there were also significant toxicities that are 
not readily ascribable to endocrine toxicity. At 10 mg/kg, the OSU-ERβ-12 compound was 
efficacious, but without some of the negative side effects measured, such as cholestasis or UGT 
deterioration. There were increased side effects with the high dose of OSU-ERβ-12, indicating 
that the side effects are only seen with a non-selective dose of the compound.  
 In conclusion, OSU-ERβ-12 fits nicely into the landscape of NASH therapeutics as a 
novel estrogen therapeutic as endocrine therapies have not been explored in NASH (Brodosi, 
2016). However, OSU-ERβ-12 is not the first SERM to be utilized in the treatment of disease. In 
fact, SERM drugs such as tamoxifen and raloxifene have long been used in the treatment of 
cancers and they are relatively well tolerated in both men and women (Wibowo, 2016). The 
potential for a SERM treatment that targets ERβ is well studied in multiple diseases, including 
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prostate and chronic inflammatory diseases, but not severe liver disease. Because the 
pathophysiology of NASH is complex and there are many different aspects involved, targeting 
NASH from different angles is desirable, and there is great promise in targeting estrogens based 
on the degree of sexual dimorphism seen in NASH patients (Kur, 2020).  
In addition, the experimental model that we used to depict NASH fibrosis was purposeful 
in starting treatment after establishing liver damage with the CCl4. This model is closer to what 
would be seen in a patient, as most patients do not start intervention drugs before they have 
significant fibrosis. Most NASH patients will have a significant amount of fibrosis in their liver 
before starting treatment, so a drug that can ameliorate existing fibrosis as well as prevent new 
fibrosis is critical. Our data suggests that OSU-ERβ-12 can ameliorate fibrosis, not only slowing 
it from the start of the CCl4 challenge, but also ameliorating existing fibrosis and slowing the 
formation of more fibrotic tissue. This study also shows that OSU-ERβ-12 shows considerable 
improvement as compared to LY500307, both in the sense of toxicity as well as efficacy in a 
mouse model. OSU-ERβ-12 is promising, not only in terms of SERMs, but also as a treatment 











Figure 4. Uterine weight by treatment group (A) Relative uterine wet weight by 
treatment group. OSU-ERb-12 (WT) doses of 100 and 300 mg/kg significantly 
increased weights compared to controls (p<0.0001), Dunnett’s multiple 
comparisons test. The LY500307 treatment groups were not different from the 
vehicle controls. (B) Relative uterine blotted weight by treatment group. WT-IV-12 
doses of 30, 100 and 300 mg/kg significantly increased weights compared to 
controls (p<0.0001), Dunnett’s multiple comparisons test. The LY500307 treatment 









Figure 5. Representative photomicrographs of uterine left horn from 
experimental mice. (A) 200x total magnification of the left uterine horn of a 
mouse from the 5% DMSO, 5% Tween 20 vehicle (OSU-ERβ-12 control) group. 
Shows normal juvenile uterine histomorphology: single layer of columnar 
endometrial epithelium, and a densely populated endometrial stroma. (B) 200x 
magnification of the left uterine horn of a mouse from the subcutaneous estradiol 
group. Shows histomorphological features consistent with exposure to estrogens: 
hyperplastic, stratified endometrial epithelium, and hypertrophied, eosinophilic 
endometrial stroma. (C) 400x magnification of the uterine left horn of a mouse 
from the 3 mg/kg OSU-ERβ-12(WT) group. Shows comparatively normal juvenile 
uterine histomorphology. (D) 400x magnification of the left uterine horn of a 
mouse from the 100 mg/kg OSU-ERβ-12 group. Shows histomorphological 







Figure 6. (A) Percent of positive picrosirius red pixels shown on each liver slide. 
Figure comparing the six-week CCl4 group to the vehicle intervention groups 
(sacrificed at 8 weeks and given 4 weeks of vehicle intervention treatment). There 
was no significance between the three vehicle controls, but the amount of fibrosis 
was significantly greater in the six week CCl4 group compared to all three vehicle 
groups by Tukey’s multiple comparisons analysis (p<0.0001). (B) Histological 










Figure 7. (A) Percent of positive picrosirius red pixels (PSR) shown on the SQ 
estradiol slide compared to the SQ estradiol vehicle slide. There was no significant 
difference between the vehicle control group and the estradiol intervention group, 
indicating no reduction of fibrosis. Tukey’s multiple comparisons analysis 
(p=0.4905). (B) Representative histological staining with Picrosirius Red for the 










Figure 8. (A) Percent of positive picrosirius red pixels shown on the PO 
LY500307 liver slide compared to the PO LY500307 vehicle slide. There was a 
significant reduction of fibrosis after LY administration as compared to the vehicle 
control. Tukey’s multiple comparisons analysis (p=0.0404). (B) Representative 


















Figure 9. (A) Percent of positive picrosirius red pixels shown on the PO OSU-
ERβ-12 (WT) liver slides for 10 mg/kg and 100 mg/kg doses compared to the PO 
OSU-ERβ-12 (WT) vehicle slide and six week CCl4 only slide. There was a 
significant reduction of fibrosis after OSU-ERβ-12 (WT) administration as 
compared to the vehicle control for both dose levels. Tukey’s multiple comparisons 
analysis WT vehicle vs 10 mg/kg WT (p=0.0003) and WT vehicle vs 100 mg/kg 
WT (p=0.0127). (B) Representative histological staining with Picrosirius Red for 






























































2x upper limit C57Bl/6N
One-Way  ANOVA: p < 0.0001
Tukey's Multiple Comparisons:
**** - E2 VEH vs. E2; WT  VEH vs 100 mpk WT; 10 mpk 
WT vs. 100 mpk WT:  p <0.0001
*** - LY VEH vs. LY: p = 0.0010
ns -  WT VEH vs. 10 mpk WT: p = 0.4686
✱✱✱✱ ✱✱ ns
✱✱✱✱
Figure 10. (A) Serum ALP (U/L) in each treatment group with horizontal 
reference lines representing the median and 2x upper limit serum ALP 
levels in a C57Bl/6N mouse. There was a significant increase in serum ALP 
compared to the respective vehicle for estradiol, LY and the 100 mg/kg 
dose of OSU-ERβ-12 (WT) administration. There was no significant 
difference from the vehicle for the 10 mg/kg dose of OSU-ERβ-12 (WT). 
Tukey’s multiple comparisons analysis WT vehicle vs 10 mg/kg WT 
(p=0.4686). E2 vehicle vs E2, OSU-ERβ-12 (WT) 10 mg/kg vs 100 mg/kg 








Figure 11. (A) UGT tract weights standardized to body weight for 
each treatment group compared to their respective controls. There is a 
significant reduction for all group from their respective vehicle for all 
groups except for the 10 mg/kg OSU-ERβ-12 (WT) group. Tukey’s 
multiple comparisons test E2 and LY groups differed from their 
respective controls (p<0.0001) and OSU-ERβ-12 (WT) 100 mg/kg 
differed from the OSU-ERβ-12 (WT) vehicle (p=0.0054). (B) UGT 
tract weights for the 10 mg/kg OSU-ERβ-12 (WT) group are 
compared to weights of the LY and E2 groups. Tukey’s multiple 
comparisons test E2 vs OSU-ERβ-12 (WT) (p<0.0001) and LY vs 

































































One-Way  ANOVA: p < 0.0001
Tukey's Multiple Comparisons:
E2 VEH vs. E2: ** p = 0.0043
LY VEH vs. 5 mpk LY: p = 0.0677
WT VEH vs. 10 mpk WT-IV-12: p > 0.9999





Figure 12. (A) Testes weights standardized to body weight for 
each treatment group compared to their respective controls. There 
is a significant reduction for the estradiol group compared to the 
estradiol vehicle. Tukey’s multiple comparisons test E2 vs vehicle 
(p=0.0043). No other group showed a significant difference from 
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